447 related articles for article (PubMed ID: 7579370)
21. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.
Weisdorf DJ; Anasetti C; Antin JH; Kernan NA; Kollman C; Snyder D; Petersdorf E; Nelson G; McGlave P
Blood; 2002 Mar; 99(6):1971-7. PubMed ID: 11877268
[TBL] [Abstract][Full Text] [Related]
22. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
[TBL] [Abstract][Full Text] [Related]
23. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
24. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
25. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; Boulad F; Castro-Malaspina H; Childs BH; Gillio AP; Kernan NA
Blood; 1995 Aug; 86(4):1261-8. PubMed ID: 7632930
[TBL] [Abstract][Full Text] [Related]
27. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
[TBL] [Abstract][Full Text] [Related]
28. Influence of CD34 cell selection on the incidence of mixed chimaerism and minimal residual disease after allogeneic unrelated donor transplantation.
Socié G; Cayuela JM; Raynal B; Esperou H; Fund X; Raffoux C; Devergie A; Ribaud P; Marolleau JP; Parquet N; Sigaux F; Brison O; Gluckman E
Leukemia; 1998 Sep; 12(9):1440-6. PubMed ID: 9737694
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
[TBL] [Abstract][Full Text] [Related]
30. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
Alyea EP; Weller E; Fisher DC; Freedman AS; Gribben JG; Lee S; Schlossman RL; Stone RM; Friedberg J; DeAngelo D; Liney D; Windawi S; Ng A; Mauch P; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2002; 8(11):601-7. PubMed ID: 12463479
[TBL] [Abstract][Full Text] [Related]
31. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.
Drobyski WR; Keever CA; Roth MS; Koethe S; Hanson G; McFadden P; Gottschall JL; Ash RC; van Tuinen P; Horowitz MM
Blood; 1993 Oct; 82(8):2310-8. PubMed ID: 8400284
[TBL] [Abstract][Full Text] [Related]
32. The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia.
Drobyski WR; Hessner MJ
Leuk Lymphoma; 1998 Oct; 31(3-4):317-23. PubMed ID: 9869195
[TBL] [Abstract][Full Text] [Related]
33. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
[TBL] [Abstract][Full Text] [Related]
34. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
Kolb HJ; Schattenberg A; Goldman JM; Hertenstein B; Jacobsen N; Arcese W; Ljungman P; Ferrant A; Verdonck L; Niederwieser D; van Rhee F; Mittermueller J; de Witte T; Holler E; Ansari H;
Blood; 1995 Sep; 86(5):2041-50. PubMed ID: 7655033
[TBL] [Abstract][Full Text] [Related]
35. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome.
Marks DI; Hughes TP; Szydlo R; Kelly S; Cullis JO; Schwarer AP; Mackinnon S; Apperley J; Barrett AJ; Hows JM
Br J Haematol; 1992 Jul; 81(3):383-90. PubMed ID: 1390211
[TBL] [Abstract][Full Text] [Related]
36. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
Weisdorf DJ; Nelson G; Lee SJ; Haagenson M; Spellman S; Antin JH; Bolwell B; Cahn JY; Cervantes F; Copelan E; Gale R; Gratwohl A; Khoury HJ; McCarthy P; Marks DI; Szer J; Woolfrey A; Cortes-Franco J; Horowitz MM; Arora M;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1475-8. PubMed ID: 19822308
[TBL] [Abstract][Full Text] [Related]
37. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
38. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors.
Davies SM; DeFor TE; McGlave PB; Miller JS; Verfaillie CM; Wagner JE; Weisdorf DJ
Am J Med; 2001 Apr; 110(5):339-46. PubMed ID: 11286947
[TBL] [Abstract][Full Text] [Related]
39. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Dazzi F; Szydlo RM; Cross NC; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; Yong A; Apperley JF; Goldman JM
Blood; 2000 Oct; 96(8):2712-6. PubMed ID: 11023502
[TBL] [Abstract][Full Text] [Related]
40. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program.
McGlave P; Bartsch G; Anasetti C; Ash R; Beatty P; Gajewski J; Kernan NA
Blood; 1993 Jan; 81(2):543-50. PubMed ID: 8422471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
